根据一支研究人员的说法，一种新开发的激动抗体降低了患有阿尔茨海默氏病小鼠的淀粉样蛋白病理学，这表明其有望是该疾病的潜在治疗方法。beplay苹果手机能用吗UTHealth Houston。

The ultrastructural morphology exhibited by the 2019 Novel Coronavirus (2019-nCoV), which was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China, is seen in an illustration released by the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, U.S. January 29, 2020. Alissa Eckert, MS; Dan Higgins, MAM/CDC/Handout via REUTERS.

GSBS faculty memberZhiqiang An，博士, has been named a fellow of the National Academy of Inventors (NAI), the organization announced Dec. 7.The NAI Fellows Program highlights academic inventors who have demonstrated a spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on quality of life, economic development, and the welfare of society. Election to NAI Fellow is the highest professional distinction accorded solely to academic inventors.

Scientists have identified a protein that may help prevent immune cells from entering breast tumors and killing the cancer cells. The research, which was conducted primarily in mice, could lead to potential strategies for overcoming barriers that keep certain immune cells from attacking tumors, according to the investigators.

Research from the lab ofKyoji Tsuchikama, PhD，助理教授Texas Therapeutics Institute在布朗基金会分子医学研究所，针对乳腺癌的新潜在治疗方法已发表在6月的版本中自然通讯。

现在有几种单克隆抗体，是大量产生的治疗抗体的相同副本，可用于治疗Covid-19。但是，在持续击败这一可怕的大流行的努力中，有足够的空间可以继续改善用SARS-COV-2治疗感染，这是导致Covid-19的病毒。

A possible explanation for why many cancer drugs that kill tumor cells in mouse models won’t work in human trials has been found by researchers with The University of Texas Health Science Center at Houston (UTHealth) School of Biomedical Informatics and McGovern Medical School.

beplay苹果手机能用吗德克萨斯大学休斯顿大学健康科学Beplay体育中心中心（UTHEADY）和德克萨斯大学医学分支的研究人员（UTMB Health）发现了Covid-19的潜在新抗体疗法。该研究发表在自然通讯。

The annual symposium of the CPRIT Therapeutic Antibody Core took place on Friday, December 11, 2020, from 1:00 pm Central Time. For the safety of participants during the COVID-19 pandemic, the symposium was held online via WebEx. Speakers highlighted the core’s capacities and provided examples of successful core collaborations.

CPRIT治疗抗体核心的年度研讨会于2019年12月10日星期二在休斯顿大学德克萨斯大学健康科学中心（休斯顿 - 休斯顿）。演讲者强调了核心的能力，并提供了成功的核心合作示例。

On January 10, 2020, Dr. Zhiqiang An was入选肯塔基大学农业学院，食品和环境校友大厅。该奖项旨在表彰An博士作为癌症疗法抗体工程领域的领导者的贡献，是大学授予的最高校友奖。

Results of a Therapeutic Antibody Core collaborative project with Dr. Philipp Scherer were published in aCell Metabolism文章。